{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:34:47Z","timestamp":1789605287648,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcehepatology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jceh.2021.06.015","type":"journal-article","created":{"date-parts":[[2021,6,19]],"date-time":"2021-06-19T03:17:58Z","timestamp":1624072678000},"page":"435-439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Saroglitazar for Nonalcoholic Fatty Liver Disease: A\u00a0Single Centre Experience in 91 Patients"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7588-8516","authenticated-orcid":false,"given":"Prateek","family":"Padole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Chand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7680-4644","authenticated-orcid":false,"given":"Nishant","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6680-7227","authenticated-orcid":false,"given":"Ashish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jceh.2021.06.015_bib1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jceh.2015.02.006","article-title":"Non-alcoholic fatty liver disease and metabolic syndrome-position paper of the Indian national association for the study of the liver, endocrine society of India, Indian college of cardiology and Indian society of gastroenterology","volume":"5","author":"Duseja","year":"2015","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2021.06.015_bib2","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2013.04.013","article-title":"Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial","volume":"59","author":"Wong","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.06.015_bib3","first-page":"367","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterol. W.B. Saunders"},{"key":"10.1016\/j.jceh.2021.06.015_bib4","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/hep.22575","article-title":"Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial","volume":"49","author":"Harrison","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.06.015_bib5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.06.015_bib6","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/liv.12483","article-title":"Readiness for behaviour change in non-alcoholic fatty liver disease: Implications for multidisciplinary care models","volume":"35","author":"Stewart","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2021.06.015_bib7","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jceh.2021.06.015_bib8","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jceh.2021.06.015_bib9","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jceh.2021.06.015_bib10","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A\u00a0randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.06.015_bib11","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.31108","article-title":"Cenicriviroc treatment for\u00a0adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the Phase 2b CENTAUR study","volume":"72","author":"Ratziu","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.06.015_bib12","series-title":"The PanPPAR Agonist Lanifibranor Induces Both Resolution of NASH and Regression of Fibrosis after 24 Weeks of Treatment in Non-cirrhotic NASH: Results of the NATIVE Phase 2b Trial","author":"Francque","year":"2020"},{"key":"10.1016\/j.jceh.2021.06.015_bib13","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jceh.2021.06.015_bib14","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jceh.2021.06.015_bib15","first-page":"S1542","article-title":"A Phase 2 double blinded, randomized controlled trial of saroglitazar in patients with nonalcoholic steatohepatitis","author":"Siddiqui","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2021.06.015_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of nonalcoholic fatty liver disease: a randomized controlled double-blind Phase 2 Trial","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.06.015_bib17","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A\u00a0Placebo-Controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jceh.2021.06.015_bib18","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.dsx.2020.08.039","article-title":"Efficacy and safety of saroglitazar in managing hypertriglyceridemia in type-2 diabetes: a meta-analysis","volume":"14","author":"Dutta","year":"2020","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.jceh.2021.06.015_bib19","first-page":"1","article-title":"New dual peroxisome proliferator activated receptor agonist \u2014 saroglitazar in diabetic dyslipidemia and non - alcoholic fatty liver disease: integrated analysis of the real world evidence","author":"Kaul","year":"2019","journal-title":"Cardiovascular Diabetology. BioMed Central"},{"key":"10.1016\/j.jceh.2021.06.015_bib20","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/liv.13634","article-title":"Dual PPAR \u03b1\/\u03b3 agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models","volume":"38","author":"Jain","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2021.06.015_bib21","first-page":"7706","article-title":"Observational study of effects of saroglitazar on glycaemic and lipid parameters on indian patients with type 2 diabetes","volume":"vol. 5","author":"Chatterjee","year":"2015"},{"key":"10.1016\/j.jceh.2021.06.015_bib22","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1136\/gut.2006.112094","article-title":"Recent advances in clinical practice: benefits of lifestyle modification in NAFLD","author":"Harrison","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.jceh.2021.06.015_bib23","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/hep.28416","article-title":"Weight loss results in significant improvements in quality of life for patients with nonalcoholic fatty liver disease\u00a0: a prospective cohort study","volume":"63","author":"Tapper","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.06.015_bib24","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/jgh.13219","article-title":"Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease","volume":"31","author":"L\u00e9dinghen","year":"2016","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2021.06.015_bib25","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1002\/hep.28394","article-title":"Liver stiffness in nonalcoholic fatty liver disease: a comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy","volume":"63","author":"Cassinotto","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.06.015_bib26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jceh.2018.02.010","article-title":"Controlled attenuation parameter for assessment of hepatic steatosis in Indian patients","volume":"9","author":"Rout","year":"2019","journal-title":"J\u00a0Clin Exp Hepatol. INASL"},{"key":"10.1016\/j.jceh.2021.06.015_bib27","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/jgh.12557","article-title":"Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease","volume":"29","author":"Chan","year":"2014","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2021.06.015_bib28","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","article-title":"Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis","volume":"66","author":"Karlas","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.06.015_bib29","doi-asserted-by":"crossref","first-page":"4287075","DOI":"10.1155\/2020\/4287075","article-title":"Clinical Case series of decrease in shear wave elastography values in ten diabetic dyslipidemia patients having nafld with saroglitazar 4\u2009mg: an Indian experience","volume":"2020","author":"Roy","year":"2020","journal-title":"Case Rep Med"},{"key":"10.1016\/j.jceh.2021.06.015_bib30","first-page":"10","article-title":"Section: gastroenterology an investigator initiated prospective , single arm observational study to evaluate the safety and efficacy of saroglitazar 4 mg in patients with non-alcoholic fatty liver disease ( nafld )\/non- alcoholic steatohepatitis ( NASH )","volume":"6","author":"Hajare","year":"2019"},{"key":"10.1016\/j.jceh.2021.06.015_bib31","article-title":"An Observational study of reduction in glycemic parameters and liver stiffness by saroglitazar 4 mg in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"12","author":"Mitra","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.jceh.2021.06.015_bib32","doi-asserted-by":"crossref","first-page":"21117","DOI":"10.1038\/s41598-020-78342-x","article-title":"Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study","volume":"10","author":"Goyal","year":"2020","journal-title":"Sci Rep"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688321001584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688321001584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:11:58Z","timestamp":1760854318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688321001584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0973688321001584"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2021.06.015","relation":{},"ISSN":["0973-6883"],"issn-type":[{"value":"0973-6883","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Saroglitazar for Nonalcoholic Fatty Liver Disease: A\u00a0Single Centre Experience in 91 Patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2021.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Indian National Association for Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}